Pieris Pharmaceuticals Equity 2024

Pieris Pharmaceuticals Aktienanalyse

What does Pieris Pharmaceuticals do?

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Pieris Pharmaceuticals's Equity

Pieris Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Pieris Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Pieris Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Pieris Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Pieris Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Pieris Pharmaceuticals stock

What is the equity of Pieris Pharmaceuticals this year?

Pieris Pharmaceuticals has equity of 26.76 M USD this year.

What was the equity of Pieris Pharmaceuticals compared to the previous year?

The equity of Pieris Pharmaceuticals has increased/decreased by -4.19% decreased compared to the previous year.

What impact does a high equity have on investors of Pieris Pharmaceuticals?

A high equity is advantageous for investors of Pieris Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Pieris Pharmaceuticals?

A low equity can be a risk for investors of Pieris Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Pieris Pharmaceuticals affect the company?

An increase in equity of Pieris Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Pieris Pharmaceuticals affect the company?

A reduction in equity of Pieris Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Pieris Pharmaceuticals?

Some factors that can affect the equity of Pieris Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Pieris Pharmaceuticals so important for investors?

The equity of Pieris Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Pieris Pharmaceuticals take to change the equity?

To change equity, Pieris Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.